Stock Events

Stock Events

Cellectis 

$3.38
144
-$0.10-2.87% Tuesday 20:00

Statistics

Day High
3.49
Day Low
3.35
52W High
5.35
52W Low
1.33
Volume
50,868
Avg. Volume
-
Mkt Cap
244.46M
P/E Ratio
-
Dividend Yield
-
Dividend
-

Upcoming

Earnings

30JulExpected
Q3 2024
Q4 2024
Q1 2025
Q2 2025
Q3 2025
Q1 2026
Next
-0.26
-0.17
-0.08
0.01
Expected EPS
-0.2627250048
Actual EPS
N/A

Financials

-88.57%Profit Margin
Unprofitable
2019
2020
2021
2022
2023
2024
83.01MRevenue
-73.52MNet Income

Analyst Ratings

8.67Average Price Target
The highest estimate is 9.00.
From 3 ratings within the last 6 months. This is not an investment recommendation.
Buy
67%
Hold
33%
Sell
0%

People Also Follow

This list is based on the watchlists of people on Stock Events who follow CLLS. It's not an investment recommendation.
Alphabet
79493
GOOGL
Apple
69146
AAPL
Microsoft
64576
MSFT
Amazon
60260
AMZN

Competitors

This list is an analysis based on recent market events. It's not an investment recommendation.
CRISPR Therapeutics
CRSP
Mkt Cap5.42B
CRISPR Therapeutics is directly competing in the gene editing space, focusing on CRISPR/Cas9 technology, similar to Cellectis' TALEN technology for gene editing in therapeutics.
Editas Medicine
EDIT
Mkt Cap530.98M
Editas Medicine operates in the genome editing field, utilizing CRISPR technology to modify genes, directly competing with Cellectis' gene editing therapies.
Intellia Therapeutics
NTLA
Mkt Cap1.85B
Intellia Therapeutics is a competitor in the CRISPR/Cas9 genome editing technology, offering therapies that could potentially overlap with Cellectis' market in gene-edited treatments.
Sangamo Therapeutics
SGMO
Mkt Cap91.14M
Sangamo Therapeutics focuses on genomic medicine, including gene editing and gene therapy, competing with Cellectis in the development of gene-modified cell-based treatments.
Allogene Therapeutics
ALLO
Mkt Cap748.99M
Allogene Therapeutics specializes in allogeneic CAR T-cell therapies, which competes with Cellectis' approach to off-the-shelf CAR T-cell products.
Gilead Sciences
GILD
Mkt Cap166.9B
Gilead Sciences, through its acquisition of Kite Pharma, competes in the CAR T-cell therapy space, directly challenging Cellectis' CAR T-cell product pipeline.
Biomarin Pharmaceutical
BMRN
Mkt Cap11.07B
BioMarin Pharmaceutical focuses on gene therapy for genetic diseases, a field that indirectly competes with Cellectis' gene editing technologies for therapeutic applications.
Pfizer
PFE
Mkt Cap149.21B
Pfizer is involved in biopharmaceuticals, including investments in gene therapy and immunotherapy, areas that compete with Cellectis' focus on gene-edited immunotherapies.
Novartis
NVS
Mkt Cap286.54B
Novartis has a strong presence in gene therapy and CAR T-cell therapy, including the first FDA-approved CAR T-cell therapy, competing with Cellectis in the advanced therapy medicinal products space.

About

Cellectis S.A., a clinical stage biotechnological company, develops immuno-oncology products based on gene-edited T-cells that express chimeric antigen receptors to target and eradicate cancer cells. It operates through two segments, Therapeutics and Plants. The company is developing UCART19, an allogeneic T-cell product candidate for the treatment of CD19-expressing hematologic malignancies, such as acute lymphoblastic leukemia; ALLO-501 and ALLO-501A to treat relapsed/refractory diffuse large B-cell lymphoma and follicular lymphoma; ALLO-316 for the treatment of Renal Cell Carcinoma; UCART123 for the treatment of acute myeloid leukemia; and UCART22 to treat B-cell acute lymphoblastic leukemia. It is also developing UCARTCS1 and ALLO-715 for the treatment of multiple myeloma. The company has strategic alliances with Allogene Therapeutics, Inc.; Les Laboratoires Servier; The University of Texas M.D. Anderson Cancer Center; and Iovance Biotherapeutics, as well as a strategic research and development collaboration with Cytovia Therapeutics, Inc. Cellectis S.A. was founded in 1999 and is headquartered in Paris, France.
Show more...
CEO
Dr. Andre Choulika Ph.D.
Employees
216
Country
France
ISIN
US15117K1034

Listings

STU
DE
ZVA.STU
MU
DE
ZVA.MU
STU
DE
ZVAA.STU
F
DE
ZVAA.F

0 Comments

Share your thoughts

FAQ

What is Cellectis stock price today?▼
The current price of CLLS is $3.38 USD — it has decreased by -2.87% in the past 24 hours. Watch Cellectis stock price performance more closely on the chart.
What is Cellectis stock ticker?▼
Depending on the exchange, the stock ticker may vary. For instance, on exchange Cellectis stocks are traded under the ticker CLLS.
Is Cellectis stock price growing?▼
CLLS stock has fallen by -6.89% compared to the previous week, the month change is a -14.43% fall, over the last year Cellectis has showed a +131.51% increase.
What is Cellectis market cap?▼
Today Cellectis has the market capitalization of 244.46M
When is the next Cellectis earnings date?▼
Cellectis is going to release the next earnings report on July 30, 2026.
What were Cellectis earnings last quarter?▼
CLLS earnings for the last quarter are -0.18 USD per share, whereas the estimation was -0.26 USD resulting in a +30.7% surprise. The estimated earnings for the next quarter are N/A USD per share.
What is Cellectis revenue for the last year?▼
Cellectis revenue for the last year amounts to 83.01M USD.
What is Cellectis net income for the last year?▼
CLLS net income for the last year is -73.52M USD.
How many employees does Cellectis have?▼
As of June 03, 2026, the company has 216 employees.
In which sector is Cellectis located?▼
Cellectis operates in the Health & Wellness sector.
When did Cellectis complete a stock split?▼
Cellectis has not had any recent stock splits.
Where is Cellectis headquartered?▼
Cellectis is headquartered in Paris, France.